Search

Displaying results 9681 - 9690 of 10000 in total
  1. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07.

  2. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation

  3. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  4. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.

  5. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.

  6. Drug

    Oportuzumab monatox

    go.drugbank.com/drugs/DB05319
    Investigational

    and a truncated portion of Pseudomonas exotoxin A. … VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells.

  7. Drug

    VGV-1

    go.drugbank.com/drugs/DB05328
    Experimental

    VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.

  8. Drug

    Arundic acid

    go.drugbank.com/drugs/DB05343
    Investigational

    Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).

  9. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.

    Categories: GABA-A Receptor Agonists
  10. Drug

    IDD-3

    go.drugbank.com/drugs/DB05427
    Experimental

    It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells. … IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines.